Evolv now designated as "Official Fan Screening Partner of TD Garden"

Evolv Technologies Holdings, Inc. (NASDAQ:EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced that it has agreed to a multi-year renewal of its hardware and software subscription agreement with TD Garden, the 19,000+ seat multipurpose arena in Boston, Massachusetts. TD Garden, home of the NHL’s Boston Bruins and NBA’s Boston Celtics also hosts a full calendar of other sporting events, concerts, and shows annually.

The subscription renewal, which extends an original agreement struck in 2024, includes an upgrade of the Evolv Express® concealed weapons screening systems to the company’s Gen2 hardware. Evolv Express uses advanced sensor technology and AI to detect concealed threats and identify the person and location of the potential threat, while allowing people to move through checkpoints at their natural walking pace. The system is designed to screen visitors effectively while helping minimize congestion and disruptions to traffic flow at entry points. Under the new agreement, the Express units, which are deployed at all venue entry points, will be paired with Evolv eXpedite™ bag screening systems. All the new systems are currently deployed and in use at the venue.

The renewal also extends the official partnership between Evolv and the arena, under which Evolv has been designated as the "Official Fan Screening Provider of TD Garden."

"TD Garden operates at an exceptionally high volume, often hosting multiple events in a single day, which makes reliable and efficient systems essential to delivering a strong experience for both guests and staff," said Tim Townsell, SVP of Business Operations at TD Garden. "We value our continued partnership with Evolv and look forward to further enhancing operations with the Gen2 hardware and new eXpedite systems."

"We’re grateful for TD Garden’s continued trust in Evolv to support entry screening operations at such a busy and high-profile venue," noted John Baier, Evolv’s Vice President of Sports & Entertainment. "As a company, we take pride in serving one of the landmark venues in our hometown of Boston, so we’re especially pleased to continue our partnership with TD Garden for years to come."

Evolv has official partner status with nearly all of the major professional and collegiate sports properties in the Boston market. In addition to TD Garden, the company is a "Proud Partner" of the Boston Red Sox; the "Official Fan Screening Provider" of the New England Patriots, New England Revolution, and Gillette Stadium; and the "Official Fan Screening Partner" of Boston College Athletics. These official partner designations join more than 50 others held by the company, which in total counts nearly 100 sports teams and venues worldwide as customers.

About Evolv Technology

Evolv (NASDAQ:EVLV) is designed to transform human security by helping organizations detect potential threats, mitigate risk, and enhance safety using AI-powered security solutions with robust insights. Our technology has helped to create efficient and positive security screening experiences for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces. Evolv’s mission is to create a safer world to live, work, learn, and play. Evolv’s advanced systems have scanned more than 4.5 billion people since 2019. Evolv Express® and Evolv eXpedite™ have been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT). Evolv and its products have been awarded numerous awards which can be viewed on our Certifications and Awards web page. Evolv®, Evolv Express®, Evolv Insights®, Evolv Visual Gun Detection™, Evolv eXpedite™, and Evolv Eva™ are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit evolv.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Evolv Technology intends for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release, other than that are historical facts, are statements that could be deemed forward-looking statements, as well as statements regarding the Company’s strategy, financial and operational performance and growth, and efforts to create value for stakeholders. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results and actions to be materially different from any future results or actions expressed or implied by the forward-looking statements, including, but not limited to, the factors discussed under the caption "Risk Factors" in our Annual Report on Form 10‑K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 10, 2026, as well as any such factors that may be updated from time to time in our other filings with the SEC. The forward-looking statements in this press release are based upon information available to us as of the date hereof, and while we believe such information forms a reasonable basis for such statements, it may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this document, whether as a result of any new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260701561200/en/

Evolv Media Contact

Alexandra Smith Ozerkis

aozerkis@evolvtechnology.com

Evolv Investor Contact

Brian Norris

bnorris@evolvtechnology.com